ZOGENIX, INC.

Delisted

CIK 0001375151Large AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2021

Revenue

$81.69M

Net Income

$-227.41M

Total Assets

$468.49M

Equity

$178.97M

Shares Out

56.23M

Op. Cash Flow

$-185.31M

Business

ZOGENIX, INC. is a former operating company in Pharmaceutical Preparations, incorporated in Delaware. Securities are no longer actively traded on a major U.S. exchange.

Auto-generated from company profile

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Net product sales	75	10	0	0	10
Collaboration revenue	7	4	4	0	0
Total revenues	82	14	4	0	10
Cost of product sales (excluding intangible asset amortization)	5	542,000	0	0	11
Research and development	143	138	116	101	67
Selling, general and administrative	149	100	61	39	26
Intangible asset amortization	8	4	0	0	—
Acquired in-process research and development and related costs	0	11	251	0	0
Change in fair value of contingent consideration	2	9	6	1	24
Total operating expenses	306	261	433	141	130
Loss from operations	−224	−248	−430	−141	−120
Interest income	659,000	3	10	7	1
Interest expense	−15	−4	−2,000	−6,000	−3
Other income, net	11	22	516,000	10	47,000
Loss from operations before income taxes	−227	−227	−420	—	—
Income tax expense (benefit)	100,000	−17	0	0	0
Net loss	−227	−209	−420	−124	−127
Net loss per share, basic (in dollars per share)	−4.07	−3.9	−9.74	—	−4.65
Net loss per share, diluted (in dollars per share)	−4.07	−3.9	−9.74	—	−4.65
Weighted average common shares outstanding, basic (in shares)	56	54	43	—	27
Weighted average common shares outstanding, diluted (in shares)	56	54	43	—	27

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Cash and cash equivalents	101	167	62	68	294
Marketable securities	201	338	189	446	0
Accounts receivable, net	10	4	0	—	0
Inventory	5	1	0	—	—
Prepaid expenses	12	7	9	7	6
Other current assets	25	5	2	12	5
Total current assets	355	522	287	533	305
Property and equipment, net	7	9	9	3	245,000
Operating lease right-of-use assets	7	8	8	9	—
Intangible asset, net	91	99	103	—	—
Goodwill	6	6	6	6	6
Other non-current assets	3	8	1	4	4
Total assets	468	651	414	648	418
Accounts payable	22	12	8	8	3
Accrued and other current liabilities	55	55	30	—	—
Deferred revenue, current	5	5	—	—	—
Current portion of operating lease liabilities	2	2	1	1	—
Current portion of contingent consideration	14	9	26	32	0
Total current liabilities	98	83	95	58	21
Deferred revenue, non-current	3	5	7	0	—
Operating lease liabilities, net of current portion	9	10	11	12	—
Contingent consideration, net of current portion	22	34	38	46	77
Convertible debt	158	149	0	—	0
Total liabilities	290	281	169	126	—
Commitments and contingencies (Note 12)	—	—	—	—	—
Preferred stock, $0.001 par value; 10,000 shares authorized, none issued and outstanding	0	0	0	0	0
Common stock, $0.001 par value; 200,000 and 100,000 shares authorized and 56,095 and 55,736 shares issued and outstanding at December 31, 2021 and 2020, respectively	56,000	56,000	45,000	42,000	35,000
Additional paid-in capital	1,731	1,695	1,360	1,219	874
Accumulated other comprehensive loss	15,000	−71,000	379,000	3,000	0
Accumulated deficit	−1,600	−1,325	−1,115	−696	−572
Total stockholders equity	179	370	245	523	302
Total liabilities and stockholders equity	468	651	414	648	418

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Stock-based compensation	35	29	21	15	6
Depreciation and amortization	9	5	1	155,000	425,000
Deferred income taxes	0	−17	0	0	0
Noncash lease expense	1	1	1	—	—
Amortization of debt discount and issuance costs	9	2	0	0	887,000
Net accretion and amortization of investments in marketable securities	−20,000	−570,000	−5	−2	0
Acquired in-process research and development (IPR&D)	0	11	251	0	—
Other	−2,000	−205,000	−471,000	−169,000	—
Accounts receivable	−6	−4	0	0	9
Inventory	−3	−1	0	0	3
Prepaid expenses and other current assets	−25	−575,000	8	−9	−801,000
Other assets	4	−2	−6	266,000	−3
Accounts payable, accrued and other current liabilities	21	14	6	7	4
Contingent consideration liability	−2	0	0	—	—
Operating lease liability	−2	−1	12	—	—
Deferred revenue	−2	−3	13	0	−1
Net cash used in operating activities	−185	−168	−112	−112	−76
Cash paid for IPR&D assets	0	−11	−180	0	0
Purchase of Tevard note receivable	0	−5	0	0	—
Purchases of marketable securities	−416	−509	−330	−570	0
Proceeds from maturities of marketable securities	540	348	415	126	0
Proceeds from sale of marketable securities	14	13	177	0	0
Purchases of property and equipment	−83,000	−679,000	−9	−1	−76,000
Net cash provided by (used in) investing activities	137	−165	73	−445	−76,000
Payments for contingent consideration liability	−18	−15	−20	0	0
Proceeds from issuance of common stock under equity incentive plans	2	6	10	—	—
Payments of tax withholding obligation on vesting restricted stock units	−2	−2	−744,000	−1	0
Net proceeds from issuance of convertible debt	0	223	0	0	—
Payment of debt issuance costs	0	−557,000	0	0	—
Proceeds from issuance of common stock, net	0	227	43	323	291
Net cash provided by financing activities	−18	437	32	331	278
Net increase (decrease) in cash and cash equivalents	−66	105	−6	−225	202
Cash paid for interest	6	0	0	0	1
Common stock issued as consideration for asset acquisition	0	0	68	0	0
Net liabilities assumed in connection with asset acquisition	0	0	4	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is ZOGENIX, INC.'s CIK number?

ZOGENIX, INC.'s SEC CIK number is 0001375151 (1375151). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find ZOGENIX, INC.'s SEC filings?

All of ZOGENIX, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

Look up any company's CIK number →